Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

August 31, 2007

Conditions
Endometrial Cancer
Interventions
DRUG

pemetrexed disodium

Trial Locations (23)

11203

SUNY Downstate Medical Center, Brooklyn

19001

Rosenfeld Cancer Center at Abington Memorial Hospital, Abington

27216

Alamance Cancer Center at Alamance Regional Medical Center, Burlington

39216

University of Mississippi Cancer Clinic, Jackson

44060

Lake/University Ireland Cancer Center, Mentor

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

45409

David L. Rike Cancer Center at Miami Valley Hospital, Dayton

46260

St. Vincent Indianapolis Hospital, Indianapolis

57105

Avera Cancer Institute, Sioux Falls

60521

Hinsdale Hematology Oncology Associates, Hinsdale

61801

CCOP - Carle Cancer Center, Urbana

65804

St. John's Regional Health Center, Springfield

65807

Hulston Cancer Center at Cox Medical Center South, Springfield

73104

Oklahoma University Cancer Institute, Oklahoma City

74104

Cancer Care Associates - Midtown Tulsa, Tulsa

75390

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas

90095-1781

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

52242-1002

Holden Comprehensive Cancer Center at University of Iowa, Iowa City

02114

Massachusetts General Hospital, Boston

49007-3731

West Michigan Cancer Center, Kalamazoo

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

44106-5065

Case Comprehensive Cancer Center, Cleveland

43214-3998

Riverside Methodist Hospital Cancer Care, Columbus

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT00087100 - Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer | Biotech Hunter | Biotech Hunter